|
⚲
|
| Keyboard |
| Cormorant Asset Management LP
✚
|
|
|---|---|
| CRD # | 167820 |
| SEC # | 801-79513 |
| CIK # | 0001583977 |
| AUM | 3,838.6 M (2026-05-27) |
| Employees | 12 (25% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 857-702-0370 |
| Address | 200 Clarendon Street Boston, MA 02116 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (5/27/2026) [Brochure] |
|---|
ITEM 5 – FEES AND COMPENSATION Management Fees, Performance Allocation, and Carried Interest Distributions With respect to the Hedge Fund, Cormorant receives a monthly management fee, in advance, in an amount equal to 0.1667% (2.0% annualized) of each Investor’s Series A capital account and 0.125% (1.5% annualized) of each Investor’s Series F capital account, generally calculated based on the net asset value of the applicable Investors’ investment as of the beginning of each month and computed prior to the payment or accrual of any performance allocation. The General Partner is entitled to receive an annual performance allocation equal to 20.0% of the net appreciation in the value of each Investor’s Series A capital account and 17.5% of the net appreciation in the value of each Investor’s Series F capital account, which are both subject to a customary high-water mark. Series F was available to Investors at the Hedge Fund’s launch and is currently closed. With respect to the PE Funds, Cormorant receives a quarterly management fee at the beginning of each calendar quarter in an amount equal to 0.25% (1.0% annualized) or 0.50% (2.0% annualized) of the sum of (i) the aggregate net capital contributions of each Investor in the fund attributable to the cost of investments in Portfolio Companies that have not yet made an initial public offering and (ii) the capital account balance of such Investor attributable to each Portfolio Company that has made an initial public offering, payable until the end of each of the Fund's Term, as defined in each of the Funds’ offering and governing documents. In addition, the General Partner may receive carried interest distributions (the “Carried Interest Distributions”), based on, among other factors, return of paid-in capital contributions, proceeds received by the Fund and the preferred return and subject to a clawback provision. The Carried Interest Distributions are generally deducted from proceeds distributed by the PE Funds from time to time (including upon the liquidation of the Fund) as determined by its General Partner. Additionally, PE Fund III offered limited parentship interests with 1% management fee and 30% carried interest that was calculated in the same manner noted above. The management fee, performance allocation, and Carried Interest Distributions may, in the sole discretion of Cormorant or the General Partners (as applicable), be waived, reduced, or rebated for certain Investors, including affiliates of the General Partners or Cormorant. Cormorant also receives from the Account an asset-based monthly management fee and an annual performance-based fee, subject to a customary high-water mark, in the amounts set forth in the agreement between Cormorant and the Account investor. Cormorant will reduce the management fee by 100% of (i) the Funds’ share of directors’ fees paid by Portfolio Companies to Cormorant or its affiliates and their respective managers, members, or employees directly attributable to the Funds’ investment in such Portfolio Companies and (ii) all net fee income received by Cormorant, its affiliates, and their members or employees (not otherwise employed by or engaged as a consultant or other service provider by a Portfolio Company) from Portfolio Companies directly attributable to the Funds’ investment in such Portfolio Companies. Investors invested in the Advisory Clients do not have the ability to choose to be billed directly for fees incurred. Cormorant (or an affiliate) deducts fees from Investor assets invested in the Advisory Clients. Cormorant shares a portion of the management fees with Cormorant PR in exchange for the advisory services Cormorant PR provides to the Advisory Clients. Other Fees and Expenses In connection with the investment management services it provides, Cormorant will bear all of its own normal and recurring operating expenses and overhead costs, except that research and research-related expenses may be paid for through the permitted use of “soft dollars” (as described in Item 12 - Brokerage Practices). The management fee may exceed the expenses borne by Cormorant on behalf of its Advisory Clients. In addition to fees payable to Cormorant, the Advisory Clients, and therefore their respective Investors, may pay a variety of expenses related to each Advisory Client’s investments and operations, including, without limitation, brokerage and other transaction costs, clearing and settlement charges, trade break fees, consulting expenses, research expenses (including research-related travel expenses), legal fees and other expenses in connection with conducting due diligence and negotiating the terms of certain investments, custodial fees, initial and variation margin, interest and commitment fees on debit balances or borrowings, stock borrowing fees and proxy solicitation expenses, legal expenses, audit and tax preparation expenses, accounting fees, costs of the administration of the Advisory Clients (including, but not limited to, fees and expenses of an administrator and third party valuation services), regulatory costs and expenses (including filing and licensing fees), organizational expenses, premiums for liability insurance, fees for risk management services, indemnification expenses, entity-level taxes, issue or transfer taxes, costs of reporting to Investors, costs of litigation, any extraordinary expenses, and other similar expenses related to the Advisory Clients. Certain Advisory Clients, including the PE Funds, will also bear expenses related to the purchase, sale, recapitalization, or refinancing of Portfolio Companies (including broken deal expenses), placement agent fees, legal fees, and other expenses in connection with conducting due diligence and negotiating the terms of investments in Portfolio Companies. |
| Account Minimums and Types of Clients — Form ADV Part 2A (5/27/2026) [Brochure] |
|---|
ITEM 7 – TYPES OF CLIENTS As previously described in Item 4, Cormorant’s clients consist of the Hedge Fund, the PE Funds, and the Account. Investors in the Hedge Fund and the PE Funds consist of institutional investors and other sophisticated investors. The minimum investment for an Investor in the Hedge Fund is $1,000,000, which may be reduced by the Onshore Feeder’s General Partner or the Offshore Feeder’s Board of Directors, as applicable. The interests in the Onshore Feeder may only be purchased by investors that are “accredited investors,” as defined in Regulation D under the Securities Act of 1933, as amended (the “Securities Act”), and “qualified purchasers,” as defined in Section 2(a)(51)(A) of the Investment Company Act of 1940, as amended. U.S. investors in the Offshore Feeder must also be “accredited investors” and “qualified purchasers.” Shares in the Offshore Feeder are typically offered to eligible investors that are not U.S. persons or U.S. tax-exempt entities. The minimum capital commitment for an Investor in the PE Funds is $5,000,000. The General Partner, in its discretion, reserves the right to reject or accept only a portion of the capital commitment of any prospective Investor. Capital commitments of lesser amounts may be accepted at the General Partner’s discretion. The interests are being offered only to investors that are “accredited investors” and “qualified purchasers.” The General Partner may admit certain friends and family as Investors on terms that are more preferential than those that are generally available to Investors. The Account was established for a sophisticated institutional investor and involves a significant minimum investment. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Praxis Precision Medicines Inc | 0.3 | ||
| Helix Acquisition Corp II | 0.2 | ||
| Psivida Corp | 0.1 | ||
| Edgewise Therapeutics Inc | 0.1 | ||
| Erasca Inc | 0.1 | ||
| Rapport Therapeutics Inc | 0.1 | ||
| Alumis Inc | 0.1 | ||
| Abivax Sa | 0.1 | ||
| Helix Acquisition Corp | 0.1 | ||
| Magenta Therapeutics Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Cormorant Private Healthcare Fund VI LP | [2026-02-11] | 75.2 M | 102.9 M |
| Offered $400,000,000 · Filed 2025-11-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining $324,800,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Cormorant Private Healthcare Fund V LP | [2023-11-13] | 318.0 M | 491.7 M |
| Offered $318,000,000 · Filed 2024-08-08 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $5,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Cormorant Private Healthcare Fund IV LP | [2021-11-15] | 252.7 M | 426.3 M |
| Offered $400,000,000 · Filed 2021-08-03 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $147,314,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Cormorant Private Healthcare Fund III LP | [2020-11-27] | 206.3 M | 429.5 M |
| Offered $419,913,000 · Filed 2021-06-16 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $213,650,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Cormorant Private Healthcare Fund II LP | [2018-11-26] | 105.5 M | 125.2 M |
| Offered $350,000,000 · Filed 2018-08-17 (D) · Exemption 506(b), 3(c)(7) · Remaining $244,450,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Cormorant Private Healthcare Fund I LP | [2016-03-30] | 29.0 M | 49.8 M |
| Offered $250,000,000 · Filed 2016-01-15 (D) · Exemption 506(b), 3(c)(7) · Minimum $5,000,000 · Remaining $221,040,010 · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Cormorant Global Healthcare Master Fund LP | [2013-06-14] | 589.2 M | 2,204.4 M |
| Filed 2026-03-03 (D/A) · Exemption 506(b) · Minimum $250,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 15 | 3.8 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 1 | 0.0 |
| Total | 16 | 3.8 |
| By Discretionary | ||
| Discretionary | 16 | 3.8 |
| Non-Discretionary | 0 | 0.0 |
| Total | 16 | 3.8 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.8 | |
| United States Persons | 3.1 | |
| Total | 16 | 3.8 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Kevin Phillip | Director | 193 | 39 | |
| Paras Malde | Director | 77 | 26 | |
| Dms Fund Governance I Ltd | Director | 10 | 4 | |
| Jay Scollins | Executive Officer | 17 | 3 | |
| Dms Fund Governance II Ltd | Director | 6 | 3 | |
| Bihua Chen | Executive Officer | 48 | 2 | |
| Cormorant Asset Management LP | Executive Officer, Promoter | 12 | 2 | |
| Caleb Tripp | Executive Officer | 8 | 2 | |
| Cormorant Asset Management LLC | Executive Officer, Promoter | 4 | 2 | |
| Cormorant Private Healthcare GP II LLC | Executive Officer | 2 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001583977] | |
| 3 | [0001583977] | |
| 4 | [0001583977] | |
| SC 13D | [0001583977] | |
| SC 13G | [0001583977] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
SAV Acquisition Corp CRBP
Common Stock
|
2025-12-11 | Sell | 30,029 | $11.46 | 344,132 |
|
EyePoint Inc EYPT
Common Stock
|
2025-12-04 | Sell | 60,000 | $15.70 | 942,000 |
|
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
|
2025-09-30 | Sell | 5,827 | $6.96 | 40,556 |
|
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
|
2025-09-29 | Sell | 2,800,000 | $6.61 | 18,508,000 |
|
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
|
2025-09-29 | Sell | 3,390,943 | $7.58 | 25,703,348 |
|
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
|
2025-09-29 | Sell | 232,460 | $8.40 | 1,952,664 |
|
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
|
2025-09-29 | Sell | 70,748 | $9.38 | 663,616 |
|
Biomea Fusion Inc BMEA
Stock Option (Right to Buy) · derivative
|
2025-06-11 | Grant | 91,970 | $0.00 | |
|
OnKure Therapeutics Inc OKUR
Class A Common Stock
|
2025-05-15 | Sell | 1,813,439 | $1.85 | 3,354,862 |
|
OnKure Therapeutics Inc OKUR
Class A Common Stock
|
2025-05-12 | Sell | 24,300 | $1.99 | 48,357 |
|
Aardvark Therapeutics Inc AARD
Series C Convertible Preferred Stock · derivative
|
2025-02-14 | Conversion | 6,780,810 | ||
|
Aardvark Therapeutics Inc AARD
Common Stock
|
2025-02-14 | Buy | 187,500 | $16.00 | 3,000,000 |
|
Aardvark Therapeutics Inc AARD
Common Stock
|
2025-02-14 | Conversion | 800,189 | ||
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-11-04 | Buy | 184,331 | $21.70 | 3,999,983 |
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-10-16 | Buy | 7,150 | $24.03 | 171,814 |
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-10-16 | Buy | 39,743 | $23.22 | 922,832 |
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-10-16 | Buy | 3,107 | $25.22 | 78,359 |
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-10-15 | Buy | 63,173 | $5.92 | 373,984 |
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-10-15 | Buy | 33,343 | $6.42 | 214,062 |
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-10-15 | Buy | 8,900 | $7.31 | 65,059 |
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Hudson Structured Capital Management Ltd
✚
|
CT | 4,028.4 M |
|
Glade Brook Capital Partners LLC
✚
|
CT | 3,955.0 M |
|
Avenue Europe International Management LP
✚
|
NY | 3,912.4 M |
|
Cyrus Capital Partners LP
✚
|
NY | 3,866.5 M |
|
Tree Line Capital Partners LLC
✚
|
CA | 3,847.7 M |
|
Vector Capital Management LP
✚
|
CA | 3,751.0 M |
|
Anchorage Capital Group LLC
✚
|
NY | 3,707.6 M |
|
Resource Capital Investment Corporation
✚
|
CA | 3,706.7 M |
|
Boussard & Gavaudan Investment Management LLP
✚
|
3,679.1 M | |
|
Soleus Capital Management LP
✚
|
CT | 3,663.3 M |